Ovarian Cancer | Clinical

December 01, 2021

Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.

November 30, 2021

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

November 29, 2021

Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.

November 25, 2021

Dana Chase, MD of Arizona Oncology, discusses frontline treatment of ovarian cancer and the challenges faced in the community oncology setting.

November 18, 2021

Stephanie L. Wethington, MD, MSc, discusses results of a study of olaparib plus ceralasertib for overcoming resistance to PARP inhibition.

November 12, 2021

The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.

November 04, 2021

The combination of dendritic cell-based immunotherapy in the second-line of treatment for patients with ovarian cancer proves beneficial.

October 27, 2021

Patients with advanced ovarian cancer who respond to platinum-based chemotherapy are eligible for olaparib monotherapy. Data from the SOLO1 trial found that the safety profile of the agent is manageable.

October 25, 2021

With a fast track designation for platinum-resistant ovarian cancer, development of the agent in this disease state will be expedited to potentially fill an unmet medical need.

October 24, 2021

The treatment of platinum-resistant ovarian cancer is challenging, with limited therapeutic options. Antibody-drug conjugates as single agents or in combinations are showing promise for these patients.